Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Rhea-AI Summary

Reviva (NASDAQ: RVPH) will present data on negative symptoms for brilaroxazine from the Phase 3 RECOVER program at CNS Summit 2025 in Boston.

The presentation covers results from the double‑blind RECOVER trial in acute exacerbation of schizophrenia and the long‑term open‑label extension in clinically stable patients over one year. Poster Number 32 is scheduled for Nov 3 and Nov 4, 2025, 5:00–7:00 PM ET. The conference runs Nov 2–5, 2025. Abstracts and additional details are available on the CNS Summit 2025 website.

CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER double-blind trial in patients with acute exacerbation of schizophrenia, and from the long-term open-label extension trial in clinically stable schizophrenia patients will be presented as a poster presentation at the CNS Summit 2025, taking place November 2-5, in Boston, Massachusetts.

Details for the poster presentation can be found below:

Title: Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year

Poster Number: 32

Date and Time: Monday, November 3^rd and Tuesday November 4^th from 5:00- 7:00 PM ET

Abstracts and additional details can be found at the CNS Summit 2025 website.

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

FAQ

What data will Reviva (RVPH) present at CNS Summit 2025?

Reviva will present negative symptom data for brilaroxazine from the Phase 3 RECOVER double‑blind trial and the 1‑year open‑label extension.

When and where is Reviva's brilaroxazine poster presentation (RVPH)?

Poster Number 32 will be presented in Boston on Nov 3 and Nov 4, 2025, from 5:00–7:00 PM ET during CNS Summit 2025.

What patient populations are included in the RECOVER brilaroxazine data for RVPH?

The data cover patients with acute exacerbation of schizophrenia from the double‑blind trial and clinically stable patients from the long‑term open‑label extension.

How long is the follow‑up reported for the open‑label extension in the RVPH poster?

The poster reports results from the open‑label extension covering up to one year in clinically stable patients.

Where can investors find the abstract and full poster details for RVPH at CNS Summit 2025?

Abstracts and poster details are available on the CNS Summit 2025 website.